clinical trial · NCT06784297
INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS TO TREATMENT FOR SARCOPENIC OBESITY
Immunis, Inc.·—·temporarily not available
SarcopeniaObesity and Obesity-related Medical ConditionsIMM01-STEM
brief summary
The expanded access is designed for patients requesting the treatment, and whose medical condition may benefit from treatment, but are unable to participate in any other IMM01-STEM clinical trial in their physician's opinion for reasons that include: (1) They do not meet enrollment criteria, or (2) They cannot perform the assessment of outcomes, or (3) The trial site is not geographically accessible.
started
—
primary completion
—
completion
—
last updated
Mar 6, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol